Also listed under Lung Diseases, Obstructive, Respiratory Hypersensitivity
59 trials changed in the last 30 days: 2 stopped, 25 with notable changes, 32 with minor changes only.
Withdrawn before enrolling
Eurofarma Laboratorios S.A.Phase 3 NCT07318350 Registry history of NCT07318350 on ClinicalTrials.gov (opens the registry)
Trial terminated
SanofiPhase 2 NCT06033833 Registry history of NCT06033833 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 2025 to Dec 2028
Also in this update: Interventions modified
The Foundation for Orthopaedics and Regenerative MedicinePhase 1 NCT05147688 Registry history of NCT05147688 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 31, 2030 to Jul 31, 2032
Also in this update: Study completion pushed from Dec 31, 2030 to Dec 31, 2032
University of RochesterNot applicable NCT05744869 Registry history of NCT05744869 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jun 30, 2026 to Dec 31, 2026
Indiana UniversityPhase 2 NCT04160910 Registry history of NCT04160910 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 4, 2025 to May 4, 2027
Also in this update: Primary endpoint(s) modified; Trial status changed: Recruiting → Not Yet Recruiting
Istinye UniversityNot applicable NCT07185178 Registry history of NCT07185178 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 2026 to Dec 2027
Hospital Clinic of BarcelonaNot applicable NCT06314477 Registry history of NCT06314477 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Oct 6, 2026; Study completion pushed from Mar 31, 2027 to Jun 14, 2027
GlaxoSmithKlinePhase 4 NCT06372496 Registry history of NCT06372496 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Primary completion date changed from estimate of Jan 1, 2026 to Jul 30, 2026; Completed without a posted recruiting period
Mansoura UniversityNot applicable NCT06974331 Registry history of NCT06974331 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Primary completion pushed from Dec 31, 2026 to Mar 31, 2027; Interventions modified
University of LeicesterNot applicable NCT07500948 Registry history of NCT07500948 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Study completion moved earlier from Mar 30, 2029 to Dec 30, 2028; Primary completion moved earlier from Dec 31, 2028 to Oct 31, 2028
Hana SerajeddiniNot applicable NCT07816718 Registry history of NCT07816718 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 292 → 138 participants
GlaxoSmithKlinePhase 3 NCT05757102 Registry history of NCT05757102 on ClinicalTrials.gov (opens the registry)
Enrollment reduced: 2000000 → 1200000 participants
Also in this update: Interventions modified; Trial arms changed: 0 → 6
Tampere UniversityNot specified NCT06330974 Registry history of NCT06330974 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Oman Medical Speciality BoardPhase 2 NCT07112456 Registry history of NCT07112456 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Oct 1, 2026 to Oct 2, 2026
Chiesi Farmaceutici S.p.A.Phase 1 NCT07851623 Registry history of NCT07851623 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 2 → 8 locations
PfizerPhase 3 NCT07772921 Registry history of NCT07772921 on ClinicalTrials.gov (opens the registry)
Recruitment opened
GlaxoSmithKlinePhase 3 NCT07782996 Registry history of NCT07782996 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 15 locations; and 1 more change in the last 30 days
GlaxoSmithKlinePhase 3 NCT07645248 Registry history of NCT07645248 on ClinicalTrials.gov (opens the registry)
Recruitment opened
GlaxoSmithKlinePhase 3 NCT07780643 Registry history of NCT07780643 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 1 → 20 locations
AstraZenecaNot applicable NCT07718724 Registry history of NCT07718724 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Trial sites reduced: 160 → 86 locations; Primary completion date changed from estimate of Nov 3, 2028 to Sep 21, 2026
AstraZenecaPhase 3 NCT06750289 Registry history of NCT06750289 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 30, 2026 to Dec 5, 2025
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 2 NCT05593250 Registry history of NCT05593250 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 47 → 44 locations
AstraZenecaNot specified NCT06521229 Registry history of NCT06521229 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Sep 19, 2026 to Nov 2, 2026; Final enrollment: 649 participants (planned 724)
Teva Branded Pharmaceutical Products R&D LLCPhase 3 NCT06664619 Registry history of NCT06664619 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 670 participants (planned 600)
Novartis PharmaceuticalsNot specified NCT05217810 Registry history of NCT05217810 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 22 participants (planned 60)
Duke UniversityNot applicable NCT05608668 Registry history of NCT05608668 on ClinicalTrials.gov (opens the registry)
Trial completed
Basque Health ServiceNot applicable NCT06437444 Registry history of NCT06437444 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Basque Health ServiceNot applicable NCT07642388 Registry history of NCT07642388 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 30, 2026 to Dec 31, 2026
Johns Hopkins UniversityPhase 2 NCT06273072 Registry history of NCT06273072 on ClinicalTrials.gov (opens the registry)
Trial status changed: Unknown → Completed
Also in this update: Study completion date changed from estimate of Aug 31, 2024 to Sep 30, 2024
Chulalongkorn UniversityNot applicable NCT06407011 Registry history of NCT06407011 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Also in this update: Primary completion date changed from estimate of Jun 30, 2026 to May 7, 2026; Final enrollment: 15 participants (planned 30)
Medical University of ViennaNot specified NCT07049978 Registry history of NCT07049978 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jan 2027 to Jul 2027
Assistance Publique - Hôpitaux de ParisNot applicable NCT06902766 Registry history of NCT06902766 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Tulane UniversityNot applicable NCT04331353 Registry history of NCT04331353 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 15, 2027 to Sep 8, 2026
Andrew D. Luster, M.D.,Ph.D.Not applicable NCT03455959 Registry history of NCT03455959 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jun 30, 2026 to May 12, 2026
Columbia UniversityNot applicable NCT05091034 Registry history of NCT05091034 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 150 → 154 locations
AstraZenecaPhase 3 NCT06307665 Registry history of NCT06307665 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 108 → 132 locations
And 1 more change in the last 30 days
Generate BiomedicinesPhase 3 NCT07359846 Registry history of NCT07359846 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 110 → 123 locations
And 1 more change in the last 30 days
Generate BiomedicinesPhase 3 NCT07276724 Registry history of NCT07276724 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 7 locations
Kymera Therapeutics, Inc.Phase 2 NCT07677059 Registry history of NCT07677059 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 71 → 81 locations
Kymera Therapeutics, Inc.Phase 2 NCT07323654 Registry history of NCT07323654 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 132 → 137 locations
PfizerPhase 2 NCT06977581 Registry history of NCT06977581 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 230 → 221 locations
SanofiPhase 2 NCT06676319 Registry history of NCT06676319 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 127 → 150 locations
SanofiPhase 2 NCT06609239 Registry history of NCT06609239 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 62 → 71 locations
SanofiNot specified NCT07556159 Registry history of NCT07556159 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Mar 2027 to Mar 1, 2029
University of NebraskaNot applicable NCT06524856 Registry history of NCT06524856 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Macleods Pharmaceuticals LtdPhase 3 NCT06618105 Registry history of NCT06618105 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2024); last known: Active, Not Recruiting
Changi General HospitalPhase 2 NCT05417906 Registry history of NCT05417906 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Foundation University IslamabadNot applicable NCT06660537 Registry history of NCT06660537 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Peking University Third HospitalNot specified NCT06621056 Registry history of NCT06621056 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Recruiting
Franciscus Gasthuis & Vlietland (Hospital)Not applicable NCT06230458 Registry history of NCT06230458 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Ain Shams UniversityNot specified NCT05632081 Registry history of NCT05632081 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
University of South FloridaNot applicable NCT05572177 Registry history of NCT05572177 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-13 | NCT07870980 Changing Lifestyle to Improve Quality of Life in Spanish Adolescents With Asthma | Universitat Internacional de Catalunya new | |
| 2026-10-07 | NCT07864506 Testing the Effects of Temperature & Humidity on Children With and Without Asthma in an… | University of Ontario Institute of Technology new | |
| 2026-10-02 | NCT07856667 COINCIDE: Cardineurovascular dIsease and Obstructive Airway Disease | VASCage GmbH new | |
| 2026-10-02 | NCT07856407 Educational Needs of Patients With Severe Asthma on Targeted Immunotherapies | University Hospital, Angers new | |
| 2026-09-23 | NCT07836764 Validation of 1 Minute Sit-to Stand Test for Assessment of Breathlessness at Exertion in… | Jacob Sandberg new | |
| 2026-09-16 | NCT07823842 T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in… | Shanghai Pulmonary Hospital, Shanghai, China new | |
| 2026-09-14 | NCT07816718 Sustained Asthma Remission and Reduced Relapse Using a Comprehensive Management Strategy… | Hana Serajeddini new | |
| 2026-09-11 | NCT07815730 Development and Validation of the Indian Asthma Care Bundle for Reducing Readmission and… | Ahmedabad University new | |
| 2026-09-11 | NCT07815925 Childhood Infection and Immunity Longitudinal Cohort | Zhejiang Provincial Center for Disease Control and Prevention new | |
| 2026-08-28 | NCT07791992 Combination of High-flow Nasal Oxygen (Optiflow) and Vibrating Membrane Nebuliser… | Centre Hospitalier Sud Francilien new |
| Early Phase 1 | 4 | |
| Phase 1 | 23 | |
| Phase 1/2 | 4 | |
| Phase 2 | 68 | |
| Phase 2/3 | 6 | |
| Phase 3 | 52 | |
| Phase 4 | 38 |
AstraZeneca (30) · GlaxoSmithKline (12) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · University of Colorado, Denver (7) · Brigham and Women's Hospital (6) · Chinese University of Hong Kong (6) · Henan University of Traditional Chinese Medicine (6) · Chiesi Farmaceutici S.p.A. (5) · Copenhagen Studies on Asthma in Childhood (5) · First Affiliated Hospital of Ningbo University (5)